BEAM
Beam Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.88 / 10
Netural
Liquidity flow evaluation is robust at 7.77/10, indicating strong fund inflows. However, analyst sentiment is mixed: UBS rates it Neutral and Bernstein rates it Buy, with both historical win rates at 0.0%, suggesting uncertainty. The overall pattern shows positive flow but conflicting analyst opinions, creating a neutral outlook.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-07
InstitutionUBS
Times predicted1
Historical Win Rate0.0%
What is the market sentiment for BEAM?
- BEAM holds a Bearish analyst rating, with 50% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.88/10 (Netural).
